Member Info for bootnk19222

😂Balls to that I’ll just buy some tarot cards , way more accurate😳

I’m surprised that there’s no discussion on potential deal figures, potentially multiple deal figures and ultimate TO price post deal. This is a P3 asset with the potential to address a 100 billion market almost overnight. P3 asset with advanced approval , zero side affects etc. apparently chartist voodoo is the order of the day ffs. There’s a reason the money is poring into this asset . The management have expressed their off the scale excitement as they are obviously in the know. How much upfront payment , stage payment and royalties for an advanced p3 asset. How much for a post deal inevitably TO price ?

😂😂😂 yep that’s the world of chartists 😂, absolute nonsense

With the multiple interviews and the ultra confident ‘deal before Xmas’ statements , it would suggest that a deal/deals have already been worked out and were just awaiting patient application. Now just a case of legal teams working through the fine details before sign off. AIMO

What the combination of verbal + nonverbal suggests strategically

Putting the verbal and nonverbal together, here’s what I infer:

• They are in “credibility building” mode. The management is making sure investors, partners, analysts understand the science, understand what’s novel about P140, and believe in management’s ability to deliver.

• They want to justify the recent share price rise / re-rating. By doing detailed interviews, stating firm scientific arguments, patent scope etc., they help reinforce to the market that the revaluation has basis, not just speculation.

• They may be positioning for partnerships / licensing or raising further capital. Solid science + strong intellectual property + clear messaging = better positioning for dealmaking or investment.

• Managing expectations but leaning optimistic. They do mention the challenges ahead (not always in detail), but the tone suggests that these are manageable, and that the upside is large.

• Minimizing risk narrative. By focusing on what is well known (patent filing, proven MOA, earlier data) rather than emphasizing uncertainties, they seem to want to reduce investor fear

It’s probably your crack carrot

Looking good all the way to 18

12.855 to sell

12.96 to sell

Get them whilst they’re hot

The gamble is buy now hoping NHS news lands, and it’s good, before they need to place. For me it would be wait until placing . All a massive gamble either way

You on the same meds as carrot ?

I’d love to know how you people calculate these ridiculous statements. How can this possibly hold at .5 when there’s a massive discounted placing within 10 days? The only way this will not be below .3 is if they’ve got a loan sorted with the share placing permission held in reserve as a just in case. Given the BODs track record of total and utter incompetence what are the odds?

What you think there won’t be a placing ? 😂😂😂

Someone bought in too high 😂😂 amateur muppet

Placing price of .2 to .25, 4 k ready for a massive gamble.

More pumping today, just keep in the back of your mind a discount placing is on the way. The gamble , do they place before or after nice news and will nice news be as good as some expect ?

Def weird buying pre massive discount placing , stupidity or inside info ?

Lots of ramping going on, lots of new members😳😂. Wonder what the placing price will be post YES vote? .2 to .25 is my guess.

(my view)

• Takeover/control move in 2025: ~35–40% chance.

• The shareholder register games, endless dilution, and survival mode all point toward someone preparing for a control grab.

• If NICE negative: chance jumps to ~60% (directors can frame takeover as “rescue or bust”).

• If NICE positive: chance drops to ~25–30% short term (since share price may lift and GDR has some optionality), but takeover still likely medium term because they’ll need a partner to fund scaling.

⸻

🎯 Bottom line

• This isn’t a wild conspiracy — it’s consistent with how distressed biotechs get picked off.

• The most likely outcome is lowball takeover/rescue at or just above the placing price (0.5p–1p).

• The chance isn’t >50% yet, but it’s a very live scenario — especially if NICE disappoints.